臨床泌尿器科64巻2号

2010年02月発行

綜説

末梢血循環癌細胞（CTC）検出

著者： 桶川隆嗣¹

所属機関： ¹杏林大学医学部付属病院泌尿器科

ページ範囲：P.95 - P.109

文献概要

要旨　末しょう血循環癌細胞の測定技術進歩により，感度，特異度，再現性が向上したCellSearch System（ベリデックス社）が開発され，本邦で臨床試験が行われている。アメリカではすでに前立腺癌，乳癌，大腸癌の転移性癌においてFDAから承認されており，ある程度確立された技術である。本稿では，システム原理，測定法，主に転移性前立腺癌における臨床的意義，さらに今後の応用発展技術について論述する。

参考文献

1）Kononen J, Bubendorf L, Kallioniemi A, et al：Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4：844-847, 1998

2）Shergill IS, Rao AR, Anjum FH, et al：Tissue microarrays and their relevance to the urologist. J Urol 175：19-26, 2006

3）Bubendorf L：High-throughput microarray technologies：from genomics to clinics. Eur Urol 40：231-238, 2001

4）Olsson CA, de Vries GM, Raffo AJ, et al：Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J Urol 155：1557, 1996

5）Ellis WJ, Vessella RL, Corey E, et al：The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer. J Urol 159：1134, 1998

6）Gao C-L, Maheshwari S, Dean RC, et al：Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer. Urology 53：714, 1999

7）Freeman JA, Esrig D, Grossfeld GD, et al：Incidence of occult lymph node metastases in pathological stage C（pT3N0）prostate cancer. J Urol 154：474, 1995

8）Stone NN, Stock RG and Unger P：Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node dissection in men with localized carcinoma of the prostate. J Urol 154：1392, 1995

9）Deguchi T, Doi T, Ehara H, et al：Detection of micrometastatic prostate cancer cells in lymph nodes reverse transcriptase-polymerase chain reaction. Cancer Res 53：5350, 1993

10）Ferrari AC, Stone NN, Eyler JN, et al：Prospective analysis of prostate specific markers in pelvic lymph nodes of patients with high-risk prostate cancer. J Natl Cancer Inst 89：1498, 1997

11）Okegawa T, Nutahara K and Higashihara E：Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer. J Urol 163：1183-1188, 2000

12）Okegawa T, Noda H, Kato M, et al：Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer. Prostate 44：210-218, 2000

13）Miyake H, Hara I, Kurahashi T, et al：Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR. Clin Cancer Res 13：1192-1197, 2007

14）Terakawa T, Miyake H, Kurahashi T, et al：Improved sensitivity for detecting micrometastases in pelvic lymph nodes by real-time reverse transcriptase polymerase chain reaction（RT-PCR）compared with conventional RT-PCR in patients with clinically localized prostate cancer undergoing radical prostatectomy. BJU Int 103：1074-1078, 2009

15）Deguchi T, Yang M, Ehara H, et al：Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer. Br J Cancer 75：634-638, 1997

16）Deguchi T, Yang M and Kawada Y：Micrometastasis of prostate cancer to lymph nodes：detection by means of reverse transcription-polymerase chain reaction. J Natl Cancer Inst 89：1471-1473, 1997

17）Schwarzenbach H, Chun FK, Lange I, et al：Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. Int J Cancer 120：1465-1471, 2007

18）Mitsiades CS, Lembessis P, Sourla A, et al：Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. Clin Exp Metastasis 21：495-505, 2004

19）Allard WJ, Matera J, Miller MC, et al：Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10：6897-6904, 2004

20）Okegawa T, Nutahara K and Higashihara E：Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. J Urol 180：1342-1347, 2008

21）Petrylak DP, Ankerst DP, Jiang CS, et al：Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98：516-521, 2006

22）Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al：Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25：3965-3970, 2007

23）Collette L, Burzykowski T, Carroll KJ, et al：Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? J Clin Oncol 23：6139-6148, 2005

24）Scher HI, Warren M and Heller G：The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res 13：1488-1492, 2007

25）Okegawa T, Nutahara K and Higashihara E：Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. J Urol 181：1091-1097, 2009

26）de Bono JS, Scher HI, Montgomery RB, et al：Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14：6302-6309, 2008

27）Chen Bt, Loberg RD, Neeley CK, et al：Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology 65：616-621, 2005

28）Moreno JG, Miller MC, Gross S, et al：Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 65：713-718, 2005

29）Danila DC, Heller G, Gignac GA, et al：Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13：7053-7058, 2007

30）Olmos D, Arkenau HT, Ang JE, et al：Circulating tumour cell（CTC）counts as intermediate end points in castration-resistant prostate cancer（CRPC）：a single-centre experience. Ann Oncol 20：27-33, 2009

31）Scher HI, Jia X, de Bono JS, et al：Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer：a reanalysis of IMMC38 trial data. Lancet Oncol 10：233-239, 2009

32）Leibovici D, Spiess PE, Agarwal PK, et al：Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 109：198-204, 2007

. Int J Urol 8：374-379, 2001

34）Nishio R, Furuya Y, Nagakawa O, et al：Metastatic prostate cancer with normal level of serum prostate-specific antigen. Int Urol Nephrol 35：189-192, 2003

. BJU Int 96：303-307, 2005

36）Sella A, Konichezky M, Flex D, et al：Low PSA metastatic androgen-independent prostate cancer. Eur Urol 38：250-254, 2000

37）Kinebuchi Y, Noguchi W, Irie K, et al：Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembryonic antigen without elevation of prostrate-specific antigen：a case report. Int J Urol 14：147-149, 2007

38）Gallagher DJ, Milowsky MI, Ishill N, et al：Detection of circulating tumor cells in patients with urothelial cancer. Ann Oncol 20：305-308, 2009

39）Naoe M, Ogawa Y, Morita J, et al：Detection of circulating urothelial cancer cells in the blood using the CellSearch System. Cancer 109：1439-1445, 2007

40）Naoe M, Ogawa Y, Takeshita K, et al：Use of the CellSearch Circulating Tumor Cell Test for monitoring urothelial cancer：two case reports of metastatic urothelial cancer. South Med J 101：439-441, 2008

41）Cristofanilli M, Budd GT, Ellis MJ, et al：Circulating tumor cells, disease progression and survival in metastatic breast cancer. N Engl J Med 351：781-791, 2004

42）Cristofanilli M, Hayes DF, Budd GT, et al：Circulating tumor cells：a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23：1420-1430, 2005

43）Yagata H, Nakamura S, Toi M, et al：Evaluation of circulating tumor cells in patients with breast cancer：multi-institutional clinical trial in Japan. Int J Clin Oncol 13：252-256, 2008

44）Cohen S, Punt C, Ianott N, et al：Relationship of circulating tumour cells to tumour response, progression free survival and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26：3213-3221, 2008

45）Hiraiwa K, Takeuchi H, Hasegawa H, et al：Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol 15：3092-3100, 2008

46）Hayes DF, Walker TM, Singh B, et al：Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 21：1111-1117, 2002

47）Fehm T, Solomayer EF, Meng S, et al：Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 7：171-185, 2005

48）Shaffer DR, Leversha MA, Danila DC, et al：Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Can Res 13：2023-2029, 2007

49）Mancuso P, Colleoni M, Calleri A, et al：Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108：452-459, 2006

50）Dellapasqua S, Bertolini F, Bagnardi V, et al：Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26：4899-4905, 2008

51）Garcia JA, Rosenberg JE, Weinberg V, et al：Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. BJU Int 99：519-524, 2007

52）Richter-Ehrenstein C, Rentzsch J, Runkel S, et al：Endothelial progenitor cells in breast cancer patients. Breast Cancer Res Treat 106：343-349, 2007